SMAD2 and neoplasm: To assess whether circulating 5a-HSA can reduce TGFβ activation in the tumor microenvironment, we analyzed the activation of intracellular TGFβ signaling mediators (SMAD2/3) in different models of tumor-bearing mice after systemic administration of 5a-HSA.